Extension Study for Participants in Belzutifan Trials (MK-6482-043/LITESPARK-043)
Sponsor: Merck Sharp & Dohme LLC
ClinicalTrials ID:NCT07405164
This study is for people who have been part of previous trials involving the drug belzutifan, which is being tested for treating advanced solid tumors and tumors related to von Hippel-Lindau (VHL) disease. The study aims to understand the long-term effects of belzutifan on survival.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This study is for people who have already participated in trials with the drug belzutifan, also known as MK-6482. Belzutifan is being researched as a treatment for advanced solid tumors and tumors linked to von Hippel-Lindau (VHL) disease. Advanced solid tumors are cancers that have spread to other parts of the body or cannot be removed by surgery. VHL-related tumors occur in people with VHL disease, a genetic condition that increases the risk of certain cancers. The purpose of this extension study is to learn about the long-term effects of belzutifan and how it impacts survival.
Eligibility Criteria
Inclusion Criteria
- Participants must have advanced solid tumors or tumors related to von Hippel-Lindau disease.
- Participants must be currently receiving belzutifan treatment in a previous study.
Exclusion Criteria
- Participants who have a serious ongoing health issue from the previous study, unless they are no longer in the hospital and are stable.
- Participants who have stopped taking belzutifan due to side effects in the previous study; they can join once they resume treatment.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Karmanos Cancer Center ( Site 0108) | 48201 | Detroit | Michigan |
| START San Antonio ( Site 0104) | 78229 | San Antonio | Texas |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.